Evaluation of antifungal and antibiofilm effects of supernatant cell-free supernatant (CFS) of Lactobacillus casei alone and in combination with nystatin against Candida albicans strains
5 affiliations
- 1Department of Medical Parasitology & Mycology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
- 2Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
- 3Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran
- 4Department of Laboratory Sciences, School of Medicine, Bam University of Medical Sciences, Bam, Iran
- 5Department of Medical Parasitology & Mycology, School of Medicine, Shahed University, Tehran, Iran
Abstract
Background and Objectives:: Candida albicans (C. albicans) is the most common cause of candidiasis in immunocompromised patients. Biofilm-associated Candida can lead to treatment complications and systemic infections.
Materials and Methods:: In this study, the antifungal activity of the cell-free supernatant (CFS) derived from Lactobacillus casei was assessed against C. albicans strains. To differentiate between pH- and H2O2-mediated effects and specific metabolite activity, all antifungal and antibiofilm assays were performed using CFS that had been neutralized to pH 7.0 and treated with catalase.
Results:: The ranges of minimum inhibitory concentration (MIC) and Half-maximal inhibitory concentration (IC50) for CFS were 7.81–62.5 and 95.1–159.6 μl/ml, respectively. Using corrected FICI criteria (synergy ≤ 0.5; additive > 0.5–1.0; indifference > 1.0–4.0), additive effects were observed in 50% of strains, synergy in 20% (including the standard strain PTCC 5027), and indifference in 30%.
Conclusion:: The results demonstrate that the CFS of L. casei exhibits promising in vitro antifungal and antibiofilm activity against C. albicans. When used in combination with nystatin, L. casei CFS showed additive or synergistic effects, suggesting its potential as an adjunctive agent for further investigation. However, these findings are preliminary, and in vivo studies and clinical assessments are necessary to validate the therapeutic potential of L. casei CFS in the management of oral candidiasis.
Related
- Amelioration of chronic inflammation, insulin resistance, and gut microbiota homeostasis by a combination of Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus in obese type 2 diabetic mice
- Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis
- Vaginal Lactobacillus paragasseri may attenuate fluconazole-resistant phenotypes in the subset of Candida albicans isolates and shows potential as a probiotic adjunct in antifungal therapy
- In vitro synergistic antifungal activity of silybin-posaconazole combination against Candida auris
- Enhanced antifungal efficacy of azole drugs through combination with usnic acid
BibTeX
@article{faryabi2026evaluation,
title = {{Evaluation of antifungal and antibiofilm effects of supernatant cell-free supernatant (CFS) of Lactobacillus casei alone and in combination with nystatin against Candida albicans strains}},
author = {Omolbanin Faryabi and Elham Isaei and Samira Salari and Seyed Amin Ayatollahi Mousavi and Ehsan Salarkia and Mohammad Hossein Sobhanipoor and Pooya Ghasemi Nejad Almani and Alireza Izadi},
journal = {Iranian Journal of Microbiology},
year = {2026},
month = nov,
doi = {10.18502/ijm.v18i5.22872},
url = {https://doi.org/10.18502/ijm.v18i5.22872},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Evaluation of antifungal and antibiofilm effects of supernatant cell-free supernatant (CFS) of Lactobacillus casei alone and in combination with nystatin against Candida albicans strains
AU - Omolbanin Faryabi
AU - Elham Isaei
AU - Samira Salari
AU - Seyed Amin Ayatollahi Mousavi
AU - Ehsan Salarkia
AU - Mohammad Hossein Sobhanipoor
AU - Pooya Ghasemi Nejad Almani
AU - Alireza Izadi
PY - 2026
DA - 2026/11/06
JO - Iranian Journal of Microbiology
DO - 10.18502/ijm.v18i5.22872
UR - https://doi.org/10.18502/ijm.v18i5.22872
AB - Background and Objectives:: Candida albicans (C. albicans) is the most common cause of candidiasis in immunocompromised patients. Biofilm-associated Candida can lead to treatment complications and systemic infections. Materials and Methods:: In this study, the antifungal activity of the cell-free supernatant (CFS) derived from Lactobacillus casei was assessed against C. albicans strains. To differentiate between pH- and H2O2-mediated effects and specific metabolite activity, all antifungal and antibiofilm assays were performed using CFS that had been neutralized to pH 7.0 and treated with catalase. Results:: The ranges of minimum inhibitory concentration (MIC) and Half-maximal inhibitory concentration (IC50) for CFS were 7.81–62.5 and 95.1–159.6 μl/ml, respectively. Using corrected FICI criteria (synergy ≤ 0.5; additive > 0.5–1.0; indifference > 1.0–4.0), additive effects were observed in 50% of strains, synergy in 20% (including the standard strain PTCC 5027), and indifference in 30%. Conclusion:: The results demonstrate that the CFS of L. casei exhibits promising in vitro antifungal and antibiofilm activity against C. albicans. When used in combination with nystatin, L. casei CFS showed additive or synergistic effects, suggesting its potential as an adjunctive agent for further investigation. However, these findings are preliminary, and in vivo studies and clinical assessments are necessary to validate the therapeutic potential of L. casei CFS in the management of oral candidiasis.
SN - 2008-3289
SN - 2008-4447
ER -